Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.
Pochon C, Oger E, Michel G, Dalle JH, Salmon A, Nelken B, Bertrand Y, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rohrlich P, Paillard C, Demeocq F, Schneider P, Plantaz D, Poirée M, Eliaou JF, Semana G, Drunat S, Jonveaux P, Bordigoni P, Gandemer V. Pochon C, et al. Among authors: eliaou jf. Br J Haematol. 2015 Apr;169(2):249-61. doi: 10.1111/bjh.13272. Epub 2014 Dec 19. Br J Haematol. 2015. PMID: 25522886 Free article.
Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?
Cousin E, Oger E, Dalle JH, Bertrand Y, Pertuisel S, Pochon C, Galambrun C, Simon P, Bruno B, Paillard C, Schneider P, Rohrlich P, de La Tour RP, Freycon C, Eliaou JF, Semana G, Jonveaux P, Drunat S, Bordigoni P, Gandemer V. Cousin E, et al. Among authors: eliaou jf. Pediatr Hematol Oncol. 2020 Apr;37(3):259-268. doi: 10.1080/08880018.2020.1717697. Epub 2020 Feb 6. Pediatr Hematol Oncol. 2020. PMID: 32028812 Clinical Trial.
Response to treatment and disease progression linked to CD4+ T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection.
Gervaix A, Nicolas J, Portales P, Posfay-Barbe K, Wyler CA, Segondy M, Avinens O, Siegrist CA, Clot J, Eliaou JF, Astruc J, Corbeau P. Gervaix A, et al. Among authors: eliaou jf. J Infect Dis. 2002 Apr 15;185(8):1055-61. doi: 10.1086/339802. Epub 2002 Apr 1. J Infect Dis. 2002. PMID: 11930315
Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
Wiszniewski W, Fondaneche MC, Louise-Plence P, Prochnicka-Chalufour A, Selz F, Picard C, Le Deist F, Eliaou JF, Fischer A, Lisowska-Grospierre B. Wiszniewski W, et al. Among authors: eliaou jf. Immunogenetics. 2003 Feb;54(11):747-55. doi: 10.1007/s00251-002-0521-1. Epub 2003 Jan 16. Immunogenetics. 2003. PMID: 12618906
One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.
Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, Guigues A, Merle C, Atoui N, Fernandez C, Le Moing V, Barbuat C, Marin G, Nagot N, Sotto A, Eliaou JF, Sabatier R, Reynes J, Corbeau P. Psomas C, et al. Among authors: eliaou jf. EBioMedicine. 2016 Jun;8:265-276. doi: 10.1016/j.ebiom.2016.05.008. Epub 2016 May 10. EBioMedicine. 2016. PMID: 27428436 Free PMC article.
109 results